| Literature DB >> 32581407 |
Yukiko Okamura1, Machiko Kito2, Kazushi Yasuda2, Reizo Baba1.
Abstract
It is unsettled whether increased exercise ventilation in Fontan subjects is due to increased pulmonary dead space or augmented ventilatory drive. Twenty-six Fontan patients underwent symptom-limited treadmill cardiopulmonary exercise testing. Two groups of age- and sex- matched subjects served as controls: the biventricularly repaired (Bi, n = 18), and the "true" control (C, n = 29) groups. Peak oxygen uptake (V̇O2peak) was not different among groups (41.0 +/- 8.4 ml/min/kg, 43.5 +/- 6.6 ml/min/kg, and 45.9 +/- 11.6 ml/min/kg for Fontan, Bi, and C groups, respectively, p = 0.16). Fontan subjects, however, showed steeper alveolar ventilation/carbon-dioxide (V̇A/V̇CO2) regression slope (35.5 +/- 5.3, 28.7 +/- 3.8, and 29.5 +/- 3.0 l/ml, for Fontan, Bi, and C groups, respectively, p<0.0001), and lower end-expiratory carbon-dioxide fraction (FetCO2VAT) at ventilatory threshold (VAT) (4.4 +/- 0.5%, 5.5 +/- 0.5%, and 5.5 +/- 0.4%, for Fontan, Bi, and C groups, respectively, p<0.001). The dead-space ventilation fraction at VAT was similar among groups (0.33 +/- 0.06, 0.33 +/- 0.04, 0.35 +/- 0.05 for Fontan, Bi, and C groups, respectively, p = 0.54). In Fontan subjects, arterial oxygen saturation at rest (SaO2rest) was correlated with V̇A/V̇CO2 regression slope (r = -0.41, p = 0.04) and with FetCO2VAT (p = -0.53, p<0.01). We conclude that Fontan patients show exercise hyperventilation due to augmented central and/or peripheral ventilatory drive, which is further augmented by residual hypoxemia.Entities:
Keywords: Fontan; exercise tolerance; maximal oxygen uptake; oxygen uptake efficiency slope; ventilatory response
Mesh:
Substances:
Year: 2020 PMID: 32581407 PMCID: PMC7276415 DOI: 10.18999/nagjms.82.2.281
Source DB: PubMed Journal: Nagoya J Med Sci ISSN: 0027-7622 Impact factor: 1.131
Diagnosis of the study subjects of the 3 groups
| Fontan
| Biventricularly repaired
| Control
| |||||
| DORV+PS | 8 | AS | 4 | arrhythmias | 10 | ||
| PAIVS | 5 | VSD | 3 | Suspected LQTS | 6 | ||
| TA | 3 | CoA | 2 | Chest pain without underlying heart disease | 4 | ||
| d-TGA | 3 | DORV | 2 | History of KD without CAL | 4 | ||
| AVSD+PS | 2 | c-TGA | 2 | Pre-syncope | 3 | ||
| HLHS | 2 | TOF | 2 | WPW syndrome without PSVT | 2 | ||
| other | 3 | other | 3 | ||||
Abbreviations: AS: aortic stenosis, AVSD: atrioventricular septal defect, CAL: coronary arterial lesion, CoA: coarctation of the aorta, c-TGA: congeniltally corrected transposition of the great arteries, DORV: double outlet right ventricle, d-TGA: d-transposition of the great arteries, HLHS: hypoplastic left heart syndrome, KD: Kawasaki disease, LQTS: long-QT syndrome, PAIVS: pulmonary atresia with intact ventricular septum, PS: pulmonary stenosis, PSVT: paroxsysmal supraventricular tachycardia, TA: tricuspid atresia, TOF: tetralogy of Fallot, VSD: ventricular septal defect, WPW: Wolf-Parkinson-White syndrome
Characteristics of the subjects and the results of cardiopulmonary exercise testing in the three study groups
| Fontan
| Biventricularly repaired
| Control
| ||
| female/male | 12/14 | 8/10 | 14/15 | |
| age (y.o.) | 8.5 (3.0) | 9.8 (3.5) | 9.3 (1.6) | 0.28 |
| height (cm) | 125 (17) a,b | 137 (23) | 137 (11) | 0.02 |
| weight (kg) | 26 (10) a,b | 37 (20) | 33 (10) | 0.02 |
| HRpeak (bets/min) | 175 (18) | 171 (21) | 183 (20) | 0.07 |
| RERpeak | 1.03 (0.06) | 1.03 (0.06) | 1.03 (0.07) | 0.99 |
| V̇O2peak (ml/min) | 1066 (489) a,b | 1525 (692) | 1468 (354) | 0.004 |
| V̇O2peak(ml/min/kg) | 41.0 (8.4) | 43.5 (6.6) | 45.9 (11.6) | 0.16 |
| V̇O2VAT (ml/min) | 656 (232) a,b | 946 (373) | 939 (248) | <0.001 |
| V̇O2VAT (ml/min/kg) | 26.0 (5.3) | 28.0 (6.6) | 29.2 (8.3) | 0.24 |
| OUES (ml/min) | 1313 (443) b | 1579 (660) | 1618 (333) | 0.046 |
| OUES (ml/min/kg) | 52.6 (11.6) | 45.9 (8.9) | 50.3 (10.5) | 0.12 |
| V̇E/V̇CO2 regression slope | 35.5 (5.3) a,b | 28.7 (3.8) | 29.5 (3.0) | <0.001 |
| V̇A/V̇CO2 regression slope | 26.9 (3.4) a,b | 21.0 (2.0) | 21.6 (2.1) | <0.001 |
| FetCO2VAT (%) | 4.4 (0.5) a,b | 5.5 (0.5) | 5.5 (0.4) | <0.001 |
| PaCO2VAT (torr) | 33.7 (3.2) a,b | 40.7 (3.1) | 40.7 (2.8) | <0.001 |
| Vd/VtVAT | 0.33 (0.06) | 0.33 (0.04) | 0.35 (0.05) | 0.54 |
| OPVAT (ml/beat) | 5.2 (1.8) a,b | 7.5 (3.6) | 6.5 (1.7) | 0.006 |
| OPVAT/body mass (ml/beat/kg) | 0.21 (0.04) | 0.21 (0.03) | 0.20 (0.05) | 0.69 |
The mean values are tested by the analysis of variance (ANOVA). The post hoc tests are calculated with the Bonferroni’s method. a: p<0.05 between the Fontan group and the biventyricularly repaired group; b: p<0.05 between the Fontan group and the control group.
Abbreviations: FetCO2VAT: mixed end-expiratory carbon dioxide concentration, HRpeak: heart rate at peak exercise, OPVAT: oxygen pulse at the ventilatory anaerobic threshold, OUES: oxygen uptake efficiency slope, PaCO2VAT: arterial carbon-dioxide partial pressure at the ventilatory anaerobic threshold, RERpeak: respiratory exchange ratio at peak exercise, V̇A: alveolar minute ventilation, VAT: ventilatory anaerobic threshold, V̇CO2: carbon-dioxide production, Vd/VtVAT: the dead-space fraction at the ventilatory anaerobic threshold, V̇E: minute ventilation. V̇O2peak: oxygen uptake at peak exercise, V̇O2VAT: oxygen uptake at the ventilatory threshold.
Fig. 1Contributions of residual hypoxemia to exercise hyperventilation in Fontan patients
Relationships of alveolar ventilation/carbon-dioxide (V̇A/V̇CO2) regression slope (a), mixed end-expiratory carbon-dioxide concentration at the ventilatory threshold (FetCO2VAT, b), and arterial carbon-dioxide partial pressure at the ventilatory threshold (PaCO2VAT, c) between arterial oxygen saturation at rest (SaO2).